TREATMENT OF NEUROLOGICAL DEGENERATIVE

DISORDERS

PRIORITY

[0001 J The present application claims the benefit of Indian Provisional Patent Application No. 2683/CHE 2012 filed on (B-Jul-2012, the entire disclosure of which is relied on for all purposes and is incorporated into this application by reference.

FIELD OF THE INVENTION

{00021 This disclosiife generally relates to compounds and compositions for the treatment of neurological degenerative disorders. More particularly, this invention relates to treating subjects with a pharmaceutically acceptable dose of compounds, stereoisomers, enantiomers, crystals, esters, salts, hydrates, prodrugs, or mixtures thereof

BACKGROUND OF THE INVENTION

|O003) The etiology of neurodegenerative diseases remains enigmatic; however, evidence for defects in energy metabolism, excitotoxicity, and for oxidative damage is increasingly compelling. It is likely that there is a complex interplay between these mechanisms. Mitochondria are the major intracellular source of free radicals, and increased mitochondrial calcium concentrations enhance free radical generation. Mitochondrial D A is particularly susceptible to oxidative stress, and there is evidence of age- dependent damage and deterioration of respiratory enzyme acti vities with normal aging. This may contribute to the delayed onset and age dependence of neurodegenerative diseases. There is evidence for increased oxidative damage to macromolecules in. amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, and Alzheimer's disease. |0004] mfl animation is a self-defensive reaction aimed at eliminating or neutralizing injurious stimuli, and restoring tissue integrity, in neurodegenerative diseases mflainmation occurs as a local response driven by microglia, in the absence of leucocyte infiltration. Like peripheral inflammation, neuroinflammation may become a harmful process, and it is now widely accepted that it may contribute to the pathogenesis of many central nervous system disorders, including chronic neurodegenerative diseases.

[0005] Neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, or

Amyotrophic Lateral Sclerosis (ALS), are characterized by a loss of neurons in particular regions of the nervous system. It is believed thai this nerve cell loss underlies the subsequent decline in cognitive or motor function that patients experience in these diseases. A range of mutant genes and environmental toxins have been implicated in the cause of neurodegenerative diseases, but the mechanisms remain largely unknown. Nevertheless, current therapeutic strategies have focused on slowing cell loss by antagonizing processes that have been implicated in the degenerative process.

[0006] Managi ng acute pathology of often relies on the addressing underlying pathology and symptoms of the disease. There is currently a need in the art for new compositions to treatment or delay of the onset of neurological degenerative disorders and its associated complications progression.

SUMMARY OF TH E INVENTION

[0007] The present invention provides compounds, compositions containing these compounds and methods for using the same to treat, prevent and/or ameliorate the effects of the conditions such as neurological degenerative disorders.

[0008] The invention herein provides compositions comprising of formula 1 or pharmaceutical acceptable salts, hydrate, solvate, prodrug, enantiomer, or stereoisomer thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one or more of pharmaceutically acceptable carriers, vehicles or diluents. These compositions may be used in the treatment of neurological degenerative disorders and its associated complications.

Formula Ϊ

[0009J In certain embodiments, the present invention relates to the compounds and compositions of formul Ϊ, or pharmaceutically acceptable salts, hydrate, solvate, prodrug, enantiomer, or stereoisomer thereof,

Formula

[0010] Wherein,

R ¹ represents CH3CO-, D, H,

R" represents D,

a is independently 1 , 2, 3, 4 or 5;

a is independently 2,3 or 7;

each b is independently 3, 5 or 6;

e is independently 1 , 2 or 6;

c and d are each independently H, , -OH, -00. C ₍ - ¾-alky1. -N¾ or -COCl¾. 1.1 J In the illustrative embodiments, examples of compounds of formula I are aa set forth

(1-2)

[0012) Herein the application also provides a kit comprising any of the pharmaceutical compositions disclosed herein.. The kit may comprise instructions for use in the treatment of neurological degenerative disorders or its related complications.

£0013] The application also discloses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and any of the compositions herein. In some aspects, the pharmaceutical composition is formulated for systemic administration, oral administration,, sustained release, parenteral administration, injection, subdermal administrati n, or transdermal administration.

[001.4] Herein, the application additionally provides kits comprising the pharmaceutical compositions described herein. The kits may further comprise instructions for use in the treatment of neurological degenerative disorders or its related complications.

[0015] The compositions described herein have several uses. The present application provides, for example, methods of treating a patient suffering from neurological degenerative disorders or its related complications manifested from neurodegeneration, neurological dysfunction, metabolic conditions or disorders, metabolic syndrome, chronic diseases or disorders; Hyperinsulinerata, Insulin resistance. Glucose intolerance, Hepatol ogy, Cancer, Respiratory, Hematological, Orthopedic, Cardiovascular, Renal, Skin, Nephrological, or Ocular complications. DETAILED DESCRIPTION OF TH E INVENTION

Definitions

[001.61 s used herein, the following terms and phrases shall have the meanings set forth below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art,

[0017] The compounds of the present invention can be present in the form of pharmaceutically acceptable salts. The compounds of the present invention can also be present in the form of pharmaceutically acceptable esters (i .e., the methyl and ethyl esters of the acids of formula 1 to be used as prodrugs). The compounds of the present invention can also be solvated, i.e. hydrated. The solvation can be affected in the course of the manufacturing process or can take place i.e. as a consequence of hygroscopic properties of an initially anhydrous compound of formula 1 {hydration).

[0018] Compounds that have the same molecular formula but differ in the nature or sequence of bonding of their atoms or the arrangement of their atoms in space are termed "isomers." Isomers that differ in the arrangement, of their atoms in space are termed "stereoisomers." Diastereomers are stereoisomers wit opposite configuration at one or more chiral centers whic!i are not enantiomers. Stereoisomers bearing one or more asymmetric centers that are non~ superimposable mirror images of each other are termed "enantiomers." When a. compound has an asymmetric center, for example, if a carbon atom is bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center or centers and is described by the R- and S-sequencing rules of Cahn, lngold and Prelog, or by the manner in which the molecule rotates the plane of polarized light and designated as dextrorotatory or levorotatory (i.e., as {+ } or (-)-isomers respectively). A chiral compound can exist as either individual enantiomer or as a mixture thereof. A mixture containing equal proportions of the enantiomers is called a "racemic mixture" [0019] As used herein, the term "metabolic condition ^' " refers to an Inborn errors of metabolism (or genetic metabolic conditions) are genetic disorders that result from a defect in one or more metabolic pathways; specifically, the function of an enzyme is affected and is either deficient or completely absent,

{0020] The term "polymorph" as used herein is art-recognized and refers to one crystal structure of a given compound.

[0021 J The phrases "parenteral administration" and "administered parenterally" as used herein refer to modes of administration other than enteral and topical administration, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intraperi cardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.

10022] A "patient," "subject," or "host" to be treated by the subject method may mean either a human or non-human animal, such as primates, mammals, and vertebrates.

[00.23] The phrase "pharmaceutically acceptable" is art-recognized. In certain embodiments, the term includes compositions, polymers and other materials and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, human beings and animals without excessive toxicity, irritation, allergic response, or other problem or com lication, commensurate with a reasonable benefit/risk ratio. j002 | The phrase "pharmaceutically acceptable carrier ' is art-recognized, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition, from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of a subject composition and not injurious to the patient, in certain embodiments, a pharmaceutically acceptable carrier is non-pyrogenic. Some examples of materials which may serve as pharmaceutically acceptable carriers include: (1 ) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose, and its derivatives, such as sodium carboxym ethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil sesame oil, olive oil, corn oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; ( 15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; ( 19) ethyl alcohol; (20) phosphate buffer solutions; and (21 ) other non-toxic compatible substances employed in pharmaceutical formulations.

[0025] The term "prodrug" is intended to encompass compounds that, under physiological conditions, are converted into the therapeutically active agents of the present invention, A common method for making a prodrug is to include selected moieties that are hydro! y zed under physiological conditions to reveal the desired molecule. In other embodiments, the prodrug is converted by an enzymatic activity of the host animal. j0026| The term "prophylactic or therapeutic" treatment is art-recognized and includes administration to the host of one or more of the subject compositions, if it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, i.e., it protects the host against developing the unwanted condition, whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i .e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof). 027] The term "predicting" as used herein refers to assessing the probability according to which a neurodegenerative condition or disorder such as Neurological degenerative disorders related diseases patient will suffer from abnormalities or complication and/or terminal platelet aggregation or failure and/or death (i.e. mortality) within a defined time window (predictive window) in the future. The mortality may be caused by the central nervous system or complication. The predictive window is an interval in which the subject will develop one or more of the said complications according to the predicted probability. The predictive window may be the entire remaining lifespan of the subject upon analysis by the method of the present invention. f0028j The term "treating" is art -recognized and includes preventing a disease, disorder or condition from occurring in an animal which may be predisposed to the disease, disorder and/or condition but has not yet been diagnosed as having it; inhibiting the disease, disorder or condition, e.g., impeding its progress; and relieving the disease, disorder, or condition, e.g.. causing regression of the disease, disorder and/or condition. Treating the disease or condition includes ameliorating at least one symptom of the particular disease or condition, even if the underlying pathophysiology is not affected, such as treating the neurological condition such as Neurological degenerative disorders of a subject by administration of an agent even though such agent does not treat the cause of the condition. The term "treating", "treat" or "treatment" as used herein includes curative, preventative (e.g.. prophylactic), adjunct and palliative treatment. j0029| The phrase "therapeutically effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a salt or composition disclosed herein that produces some desired effect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time. The effective amount may vary depending on such factors as the disease or condition being ireated, the particular targeted constructs being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.

{0030] In certain embodiments, the pharmaceutical compositions described herein are formulated in a manner such that said compositions will be delivered to a patient in a therapeutically effective amount as part of a prophylactic or therapeutic treatment. The desired amount of the composition to be administered to a patient will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the salts and compositions from the subject compositions. It is to be noted that dosage values ma also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the perso administering or supervising the administration of the compositions. Typically, dosing will be determined using techniques known to one skilled in the art.

[0031] Additionally, the optimal concentration and/or quantities or amounts of any particular salt or composition may be adjusted to accommodate variations in the treatment parameters. Such treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.

[0032] In certain embodiments, the dosage of the subject compositions provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from time 0 to infinity may be used. [0053] When used with respect to a pharmaceutical composition or other material, the term "sustained release" is art-recognized. For example, a subject composition which releases a substance over time may exhibit sustained release characteristics, in contrast to a bolus type administration in which the entire amount of the substance is made biologically available at one time. For example, in particular embodiments, upon contact with body fluids including blood, spinal fluid, mucus secretions, lymph or the like, one or more of the pharmaceutically acceptable excipients may undergo gradual or delayed degradation (e.g., through hydrolysis) with concomitant release of any material incorporated therein, e.g., an therapeutic and/or biologically active salt and/or composition, for a sustained or extended period (as compared to the release from a bolus). This release may result in prolonged delivery of therapeutically effective amounts of any of the therapeutic agents disclosed herein.

[0034] The phrases "systemic administration," "administered systemica!!y," "peripheral administration' ^" and "administered peripherally" are art-recognized, and include the administration of a subject composition, therapeutic or other material at. a site remote from the disease being treated. Administration of an agent for the disease being treated, even if the agent .is subsequently distributed systemic iiy, may be termed "local" or "topical" or "regional" administration, other than directly into the central nervous system, e.g., by subcutaneous administration, such that it enters the patient's system and, thus, is subject to metabolism and other like processes. j0035| The phrase "therapeutically effective amount" is an art-recognized term. In certain embodiments, the term refers to an amount of a salt or composition disclosed herein that produces some desired eftect at a reasonable benefit/risk ratio applicable to any medical treatment. In certain embodiments, the term refers to that amount necessary or sufficient to eliminate or reduce medical symptoms for a period of time. The effective amount may vary depending on such, factors as the disease or condition being treated, the particular targeted constructs being administered, the size of the subject, or the severity of the disease or condition. One of ordinary skill in the art may empirically determine the effective amount of a particular composition without necessitating undue experimentation.

|Ο03δ] The present disclosure also contemplates prodrugs of the compositions disclosed herein, as well as pharmaceutically acceptable salts of said prodrugs. 0037J This application also discloses a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the composition of a compound of Formula I may he formulated for systemic or topical or oral administration. The pharmaceutical composition may be also formulated for oral administration, oral solution, injection, subderroal administration, or transdermal, administration. The pharmaceutical composition may further comprise at least one of a pharmaceutically acceptable stabilizer, diluent, surfactant, filler, binder, and lubricant.

{ ^' 0038 J in many embodiments, the pharmaceutical compositions described herein will incorporate the disclosed compounds and compositions (Formula I) to be delivered in an amount sufficient to deliver to a patient a therapeutically effective amount of a compound of formula I or composition as pari of a prophylactic or therapeutic treatment. The desired concentration of formula Ϊ or its pharmaceutical acceptable salts will depend on absorption, inactivation, and excretion rates of the drug as well as the delivery rate of the salts and compositions from the subject compositions. It is to be noted that dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions. Ty pically, dosing will be determined using techniques known to one skilled in the art. 0039] Additionally, the optimal concentration and/or quantities or amounts of any particuiar compound of formula 1 may be adjusted to accommodate variations in the treatment parameters. Such treatment parameters include the clinical use to which the preparation is put, e.g., the site treated, the type of patient, e.g., human or non-human, adult or child, and the nature of the disease or condition.

[0040] The concentration and/or amount of any compound of formula I may be readily identified by routine screening in animals, e.g., rats, by screening a range of concentration and/or amounts of the material in question using appropriate assays. Known methods are also availabie to assay local tissue concentrations, diffusion rates of the salts or compositions, and local blood flow before and after administration of therapeutic formulations disclosed herein. One such method is microdiaiysis, as reviewed by T. E. Robinson et al ., 1991, microdiaiysis in the neurosciences. Techniques, volume 7, Chapter 1. The methods reviewed by Robinson may be applied, in brief as follows. A microdiaiysis loop is placed in situ in a test animal. Dialysis fluid is pumped through the loop. When compounds with formula 1 suc as those disclosed herein are injected adjacent to the loop, released daigs are collected in the dialysate in proportion, to their local tissue concentrations. The progress of diffusion of the salts or compositions may be determined thereby with suitable calibration procedures using known concentrations of sails or compositions.

[0041 ] in certain embodiments, the dosage of the subject compounds of formula I provided herein may be determined by reference to the plasma concentrations of the therapeutic composition or other encapsulated materials. For example, the maximum plasma concentration (Cmax) and the area under the plasma concentratio -time curve from time 0 to infinity may be used.

10042] Generally, in carrying out the methods detailed hi this application, an effective dosage for the compounds of Formulas 1 is in the range of about 0.01 mg/kg/day to about 100 mg/kg/day in single or divided doses, for instance 0.01 mg kg day to about 50 mg/kg day in single or divided doses. The compounds of Formulas 1 may be administered at a dose of, for example, less than 0.2 mg/kg day, 0.5 mg kg/day, 1.0 mg kg day, 5 mg/kg/day, 10 mg kg/day, 20 mg/kg/day, 30 mg kg day, or 40 mg/kg/day. Compounds of Formula 1 may also be administered to a human patient at a dose of, for example, between 0.1 mg and 1000 mg, between 5 mg and 80 nig, or less than 1.0, 9,0, 12.0, 20.0, 50.0, 75.0, 100, 300, 400, 500, 800, 1000, 2000, 5000 mg per day. In certain embodiments, the compositions herein are administered at an amount that is less than 95%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, or 10% of the compound of formula I required for tiie same therapeutic benefit.

10043} An effective amount of the compounds of formula I described herein refers to the amount of one of said salts or compositions which is capable of inhibiting or preventing a disease. For example Neurological degenerative disorders or any other medical condition,

|0044} An effective amount may be sufficient to prohibit, treat, alleviate, ameliorate, iia.lt, restrain, slow or reverse the progression, or reduce the severity of a complication resulting from, nerve damage or demyelizatioii and/or elevated reactive oxidative- nitfosative species and/or abnormalities in neurotransmitter homeostasis' s, in patients who are at risk for such complications. As such, these methods include both medical therapeutic (acute) and/or prophylactic (prevention) administration as appropriate The amount and timing of compositions administered will, of course, be dependent on the subject being treated, on the severity of the affliction, on the manner of administration and on the judgment of the prescribing physician. Thus, because of patient-to-patient variability, the dosages given above are a guideli e and the physician may titrate doses of the drug to achieve the treatment that the physician considers appropriate for the patient. In considering the degree of treatment desired, the physician must balance a variety of factors such as age of the patient, presence of preexisting disease, as well as presence of other diseases.

|O045J The compositions provided by this applicatio may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary. Further, the compositions may be administered intranasally, as a rectal suppository, or using a "flash" formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water. Furthermore, the compositions may be administered to a subject in need of treatment by controlled release dosage forms, site specific drug delivery, transdermal drug delivery, patch (active/passive) mediated drag delivery, by stereotactic injection, or in nanoparticies.

|0046] The compositions may be administered alone or in combination with pharmaceutically acceptable earners, vehicles or diluents, in either single or multiple doses. Suitable pharmaceutical carriers, vehicles and diluents include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents. The pharmaceutical compositions formed by combining the compositions and the pharmaceutically acceptable carriers, vehicles or diluents are then readily administered in a variety of dosage forms such as tablets, powders, lozenges, syrups, injectable solutions and the like. These pharmaceutical compositions can, if desi red, contain additional ingredients such as flavorings, binders, excipients and the like. Thus, for purposes of oral administration, tablets containing various excipients such as L-arginine, sodium citrate, calcium carbonate and calcium phosphate may be employed along with various disintegrates such as starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium iauryl sulfate and talc are often useful for tabietting purposes. Solid compositions of a similar type may also be employed as fillers in soft and hard filled gelatin capsules. Appropriate materials for this include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration, the essential active ingredient therein may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if desired, emulsifying or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and combinations thereof. The compounds of formula 1 may also comprise enterically coated comprising of various excipients, as is well known in the pharmaceutical art. {004? I For parenteral administration, solutions of the compositions may be prepared in (for example) sesame or peanut oil, aqueous propylene glycol, or in sterile aqueous solutions may be employed. Such aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration, in this connection, the sterile aqueous media employed are all readily available fay standard techniques known to those skilled in the art.

{0048] The formulations, for instance tablets, may contain e.g. 0 to 100, 50 to 250, 1 50 to 500 mg, or 350 to 800 mg e.g. 10, 50, 1 0, 300, 500, 700, 800 mg of the compounds of formula ! disclosed herein, for instance, compounds of formula. I or pharmaceutical acceptable salts of a compounds of Formula L

{0049] Generally, a composition as described herein may be administered orally, or parenteral! y (e.g., intravenous, intramuscular, subcutaneous or intramedullary). Topical, administration may also be indicated, for example, where the patient is suffering from gastrointestinal disorder that prevent oral administration, or whenever the medication is best applied to the surface of a tissue or organ as determined by the attending physician. Localized administration may also be indicated, for example, when a high dose is desired at the target, tissue or organ. For buccal administration the active composition may take the form of tablets or lozenges formulated in a conventional manner.

|Ό050] The dosage administered will be dependent upon the identify of the neurological disease; the type of host involved, including its age, health and weight; the kind of concurrent treatment, if any; the frequency of treatment and therapeutic ratio.

J005I j illustratively, dosage levels of the administered active ingredients are: intravenous, 0. 1 to about 200 mg/kg; intramuscular, 1 to about 500 mg kg; orally, 5 to about 1000 msi/ksi; intranasal instillation. 5 to about 1000 mg/ka; and aerosol, 5 to about 1 00 mg/kg of host body weight,

[0052] Expressed in terms of concentration, an active ingredient can be present in the compositions of the present invention for localized use about the cutis, intranasaiSy, pharyngolaryfigeally, bronchially, intravaginally, rectally, or ocularly in a concentration of from about 0.01 to about 50% w w of the composition; preferably about 1 to about 20% w/w of the composition; and for parenteral use in a concentration of from about 0.05 to about 50% w/v of the composition and preferably from about 5 to about 20% w/v.

[0053] The compositions of the present: invention are preferably presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, suppositories, sterile parenteral solutions or suspensions, sterile non-parenteral solutions of suspensions, and oral solutions or suspensions and the like, containing suitable quantities of an active ingredient. For oral administration either solid or fluid unit dosage forms can be prepared.

[0054] As discussed above, the tablet core contains one or more hydrophilic polymers. Suitable hydrophilic polymers include, but are not limited to, water swellable cellulose derivatives, polyalkylene glycols, thermoplastic polyalkylene oxides, acrylic polymers, hydrocolloids, clays, gelling starches, swelling cross-linked polymers, and mixtures thereof. Examples of suitable water swellable cellulose derivatives include, but are not limited to, sodium carboxymethylcellutose, cross-linked hydroxypropylcellulose, hydroxy propyl cellulose (HPC), hydroxypropylmethylcellulose (HPMC), hydroxyisopropylceliulose, hydroxyhutylcellulose, hydroxypheriylcellulose, hydroxyethylcellulose (HEC), hydroxypentylceliulose, hydroxypropylethylcelluiose, hydroxy propylbutylcellulose, and hydroxypropylethylcelluiose, and mixtures thereof. Examples of suitable polyalkylene glycols include, but are not limited to, polyethylene glycol. Examples of suitable thermoplastic polyalkylene oxides include, but are not limited to, poly (ethylene oxide). Examples of suitable acrylic polymers include, but are not limited to. potassium methacry laiedi vinylbenzene copolymer, polymethylmethacrylate, high-molecular weight crossli ked acrylic acid homopolymers and copolymers such as those commercially available from Noveon Chemicals under the tradename CARBOPOL™ Examples of suitable hydrocolloids include, but are not limited to, alginates, agar, guar gum, locust bean gum, kappa carrageeoan, iota carrageenan, tara, gum arabic, tragacanth, pectin, xanthan gum, gel I an gum, maltodextrin, gaSactomannan, pusstulan, laminarin, scleroglucan, gum arabic, inulin, pectin, gelatin, whelan, rharasan, zooglan, methylan, chitin, cyclodextrin, chitosan, and mixtures thereof. Examples of suitable clays include, but are not limited to, smectites such as bentonite, kaolin, and laponite; magnesium tri silicate; magnesium aluminum silicate; and mixtures thereof. Examples of suitable gelling starches include, but are not limited to, acid hydrolyzed starches, swelling starches such as sodium, starch glycolate and derivatives thereof and mixtures thereof. Examples of suitable swelling cross-linked polymers include, but are not limited to, cross-linked polyvinyl pyrroJidoiie, cross-linked agar, and cross-! inked carboxymethylcellulose sodium, and mixtures thereof.

100551 The carrier ma contain one or more suitable excipients for the formulation of tablets. Examples of suitable excipients include, but are not limited to, fillers, adsorbents, binders, disintegrants, lubricants, gltdants, release-modifying excipients, superdisintegrants, antioxidants, and mixtures thereof.

{0056] Suitable binders include, but are not limited to, dry binders such as polyvinyl pyrrol i done and hydroxypropyimethylcelluiose; wet binders such as water-soluble polymers, including hydrocolloids such as acacia, alginates, agar, guar gum, locust bean, carrageenan, carboxymethylcellulose, tara, gum arable, tragacanth, pectin, xanthan, gellan, gelatin, maltodextrin, galactomannan, pusstulan, laminarin, scleroglucan, inulin, whelan, rhamsan, zooglan, methylan, chi in, cyclodextrin, chitosan, polyvinyl pyrrolidone, cellulosics, sucrose, and starches; and mixtures thereof Suitable disintegrants include, but are not limited to, sodium starch glycolate, cross-linked polyvinylpyrrolidone, cross-linked caiboxymediyicellulose, starches, microcryslallme cellulose, and mixtures thereof.

|0057] Suitable lubricants include, but are not limited to, long chain fatty acids and their salts, such as magnesium stearate and stearic acid, talc, glycerides waxes, and mixtures thereof Suitable glidants include, but are not limited to, colloidal silicon dioxide. Suitable release-modifying excipients include, but are not limited to, insoluble edible materials, pH-dependent polymers, and mixtures thereof

{ ^' 0058) Suitable insoluble edible materials for use as release-modifying excipients include, but are not limited to, water-insoluble polymers and low-melting hydrophobic materials, copolymers thereof, and mixtures thereof. Examples of suitable water- insoluble polymers include, but are not limited to, ethylcellulose, polyvinyl alcohols, polyvinyl acetate, polycaprolactones, cellulose acetate and its derivatives, acrylates, methacrylates, acrylic acid copolymers, copolymers thereof, and mixtures thereof. Suitable low-melting hydrophobic materials include, but are not limited to, fats, fatty acid esters, phospholipids, waxes, and mixtures thereof. Examples of suitable fats include, but are not limited to, hydrogen ated vegetable oils such as for example cocoa butter, hydrogenated palm kernel oil, hydrogenated cottonseed oil, hydrogenated sunflower oil, and hydrogenated soybean oil, free fatty acids and thei salts, and mixtures thereof. Examples of suitable fatty acid esters include, but are not limited to, sucrose fatty acid esters, mono-, di-, and triglycerides, glyceryl behenate, glyceryl palmitostearate, glyceryl monostearate, glyceryl tri stearate, glyceryl trilaurylate, glyceryl rayristate, lycoWax- 932, lauroyl macrogol-32 glycerides, stearoyl macrogol-32 glycerides, and mixtures thereof. Examples of suitable phospholipids include phosphoiidyi choline, phosphoiidyi serene, phosphoiidyi enositol, phosphotidic acid, and mixtures thereof. Examples of suitable waxes include, but are not limited to, carnauba wax, spermaceti wax, beeswax, candelilla wax, shellac wax, macrocrystalline wax, and paraffin wax; fat-containing mixtures such as chocolate, and mixtures thereof. Examples of super disintegrants include, but are not limited to, croscarmeliose sodium, sodium starch glycolate and cross- linked povidone (crospovidorse). In one embodiment the tablet core contains up to about 5 percent by weight of such super disintegrant.

{0059] Examples of antioxidants include, but are not limited to, tocopherols, ascorbic acid, sodium pyrosulfite, but lhydroxytoluene, butylated hydroxyanisole, edetic acid, and edetate salts, and mixtures thereof. Examples of preservatives include, ut are not limited to, citric acid, tartaric add, lactic acid, malic acid, acetic acid, benzoic acid, and sorbic acid, arid mixtures thereof .

[0060] in one embodiment, the immediate release coating has an average thickness of at least 50 microns, such as from about 50 microns to about 2500 microns; e.g., from about 250 microns to about. 1000 microns. In embodiment, the immediate release coating is typically compressed at a density of more than about 0.9 g/cc, as measured by the weight and volume of that specific layer.

{0061 | hi one embodiment, the immediate release coating contains a first portion and a second portion, wherein at least one of the portions contains the second pharmaceutically active agent, hi one embodimeiit, the portions contact each other at a center axis of the tablet. In one embodiment., the first portion includes the first pharmaceutically active agent and the second portion includes the second pharmaceutically active agent, 0062] In one embodiment, the first portion contains the first pharmaceutically active agent and the second portion contains the second pharmaceutically active agent. In one embodiment, one of the portions contains a third pharmaceutically active agent, in one embodiment one of the portions contains a second immediate release portion of the same pharmaceutically active agent as that contained in the tablet core.

|0063] In one embodiment, the outer coating portion is prepared as a dry blend of materials prior to addition to the coated tablet core, in another embodiment the outer coating portion is included of a dried granulation including the pharmaceutically active agent.

|0064] Formulations with different drug release mechanisms described above could be combined in a final dosage form containing single or multiple units. Examples of multiple units include multilayer tablets, capsules containing tablets, beads, or granules in a solid or liquid form. Typical, immediate release formulations include compressed tablets, gels, films, coatings, liquids and particles that can be encapsulated, for example, in a gelatin capsule. Many methods for preparing coatings, covering or incorporating drugs, are known in the art j0065| The immediate release dosage, unit of the dosage form, i .e., a tablet, a plurality of drug-containing beads, granules or particles, or an outer layer of a coated core dosage form, contains a therapeutically effective quantity of the active agent with conventional pharmaceutical excipients. The immediate release dosage unit may or may not be coated, and may or may not be admixed with the delayed release dosage unit or units (as in an encapsulated mixture of immediate release drug-containing granules, particles or beads and delayed release drug-containing granules or beads). 0066] Extended release formulations are generally prepared as diffusion or osmotic systems, for example, as described in "Remington The Science and Practice of

Pharmacy", 20th. Ed., Lippincott Williams & Willdns, Baltimore, Md., 2000). A diffusion system typically consists of one of two types of devices, reservoir and matrix, which are we!lfcnown and described in die art. The matrix devices are generally prepared by compressing the drug with a slowly dissolving polymer carrier into a tablet form .

|0067| An immediate release portion can be added to the extended release system by means of either applying an immediate release layer on top of the extended release core; using coating or compression processes or in a multiple unit system such as a capsule containing extended and immediate release beads. {0068 J Delayed release dosage formulations are created by coating a solid dosage form with a film of a polymer which is insoluble in the acid environment of the stomach, but soluble in the neutral environment of small intestines. The delayed release dosage units can be prepared, for example, by coating a drug or a daig-containing composition with a selected coating material. The drug-containing composition may be a tablet for incorporation into a capsule, a tablet for use as an inner core in a "coated core" dosage form., or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or capsule.

[0069] A pulsed release dosage form is one that mimics a multiple dosing profile without repeated dosing and typically allows at least a. twofold reduction in dosing frequency as compared to the drug presented as a conventional dosage form (e.g., as a solution or prompt drug-releasing., conventional solid dosage form). A pulsed release profile is characterized by a time period of no release (lag time) or reduced release followed by rapid drug rel ase.

[00701 Each dosage form contains a therapeutically effective amount of active agent. In one embodiment of dosage forms that mimic a twice daily dosing profile, approximately 30 wt % to 70 wt %, preferably 40 wt. % to 60 wt, ¾, of the total amount of active agent in the dosage form is released in the initial pulse, and, correspondingly approximately 70 wt. % to 3.0 wt, ¾, preferably 60 wt. % to 40 wt. %, of the total amount of active agent in the dosage form is released in the second pulse. For dosage forms mimicking the twice daily dosing profile, the second pulse is preferably released approximately 3 hours to less than 14 hours, and more preferably approximately 5 hours to 12 hours, following administration.

[0071 J Another dosage form contains a. compressed tablet or a capsule having a drug- containing immediate release dosage unit, a delayed release dosage unit and an optional second delayed release dosage unit. In this dosage form, the immediate release dosage unit contains a plurality of beads, granules particles that release drug substantially immediately following oral administration to provide an initiai dose. The delayed release dosage unit contains a plurality of coated heads or granules, whic release drag approximately 3 hours to 14 hours following oral administration to provide a second dose, j0072| For purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, may be prepared.

|Θ073] Methods of preparing various pharmaceutical compositions with a certain amount of one or more compounds of formula 1 or other active agents are known, or will be apparent in light of this disclosure, to those skilled in this art. For examples of methods of preparing pharmaceutical compositions, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., I 9th Edition (1995).

|007 J In addition, in certain embodiments, subject compositions of the present application maybe lyophilized or subjected to another appropriate drying technique such as spray drying The subject compositions may be administered once, or may be divided into a number of smaller doses to be administered at varying intervals of time, depending in part on the release rate of the compositions and the desired dosage.

|0075| Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of a subject corn-position which may be combined with a carrier material to produce a single dose may vary depending upon the subject bein treated, and the particular mode of administration. [007(51 Methods of preparing these formulations or compositions include the step of bringing into association subject compositions with the carrier and, optionally, one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association a subject composition with liquid carriers, or finely divided solid carriers, or both, and then, if necessary, shaping the product. j0077| The compounds of formula Ϊ described herein may be administered in inhalant or aerosol formulations. The inhalant or aerosol formulations may comprise one or more agents, such as adjuvants, diagnostic agents, imaging agents, or therapeutic agents useful in inhalation therapy. The final aerosol formulation may for example contain 0,005-90% w/w, for instance 0-005-50%, 0.005-5% w/w, or 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.

[0078] In solid dosage forms for oral administration (capsules, tablets, pills, dragees, powders, granules and the like), the subject composition is mixed with one or more pharmaceutically acceptable carriers and/or any of the following: (1) fillers or extenders, such as starches, lactose, sucrose, glucose, mannifol, and/or stiicic acid; (2) binders, such as, for example, carboxymethyl cellulose, alginates, gelatin, polyvinyl pyrrol idone, sucrose and/or acacia; (3) huroeciants, such as glycerol: (4) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (5) solution retarding agents, such as paraffin; (6) absorption accelerators, such as quaternary ammonium compounds; (7) wetting agents, such as, for exampie, acetyl alcohol and glycerol monostearate; (8) absorbents, such as kaolin and bentonite clay; (9) lubricants, such a talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium iauryl sulfate, and mixtures thereof; and (10) coloring agents. In the case of capsules, tablets and pills, the pharmaceutical compositions may also comprise buffering agents. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using lactose or milk sugars, as well as high molecular weight polyethylene glycols and the like. [00791 Liquid dosage forms for oral admimsiratkm include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs, hi addition to the subject compositions, the liquid dosage forms may contain inert diluents commonly used in the art, such as, for example, water or other solvents, solubil ^' izing agents and emukifsers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl beiizoate, propylene glycol, 1,3-butylene glycol, oils (in particular, cottonseed, corn, peanut, sunflower, soybean, olive, castor, and sesame oils), glycerol, tetrahydrofuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof

[0080) Suspensions, in addition to the subject compositions, may contain suspending agents such as, for example, eihoxviaied isostearyl alcohols, polyoxyetbylene sorbitol, and sorbitan esters, microcrysiallme cellulose, aluminum metahydroxide, bentonite, agar- agar ^" and iragacanth, and mixtures thereof

[00S1 J Formulations for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax, or a salicylate, and which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the encapsulated compound(s) and composition(s). Formulations which are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams, or spray formulations containing such carriers as are known in the art to be appropriate.

[0082] Dosage forms for transdermal administration include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. A subject composition may be mixed under sterile conditions with a pharmaceutically acceptable carrier, and with any preservatives, buffers, or propel lants that may be required. For transdermal administration, the complexes may include lipophilic and hydrophilic groups to achieve the desired water solubility and transport properties. j00S3j The ointments, pastes, creams and gels may contain, in addition to subject compositions, other carriers, such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof. Powders and sprays may contain, in addition to a subject composition, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and poiyamide powder, or mixtures of such substances. Sprays may additionall contain customary propellanis, such as ch!orofluorohydrocarbons and volatile imsubstituted hydrocarbons, such as butane and propane,

[0084] Methods of delivering a composition or compositions via a transdermal patch are known in the art. Exemplary patches and methods of patch delivery are described in US Patent Nos. 6,974,588, 6,564,093, 6,312,716, 6,440,454, 6,267,983, 6,239, 180, and 6,103,275.

|0085] In another embodiment, a transdermal patch may comprise: a substrate sheet comprising a composite ilm formed of a resin composition comprising 100 parts by weight of a polyvinyl chlorsde-poiyuf ethane composite and 2-10 parts by weight of a styrene-ethy!ene-butylene-styrene copolymer, a first adhesive layer on the one side of the composite film, and a polyaikylene terephthalate film adhered to the one side of the composite film by means of the first adhesive layer, a primer layer which comprises a saturated polyester resin and is formed on the surface of the polyaikylene terephthalate film; and a second adhesive layer comprising a styrene-diene-styrene block copolymer containing a pharmaceutical agent layered on the primer layer. A method for the manufacture of the above-mentioned substrate sheet comprises preparing the above resin composition molding the resin composition into a composite film by a calendar process, and then adhering a polyalkylene tereph thai ale film on one side of the composite film by means of an adhesive layer thereby forming the substrate sheet, and forming a primer layer comprising a saturated polyester resin on the outer surface of the polyalkylene terephthal te film.

|0086| Another type of patch comprises incorporating the drug directly in a pharaiaceiiticaiiy acceptable adhesive and laminating the drug-containing adhesive onto a suitable backing member, e.g. a polyester backing membrane. The drug should be present at a concentration which will not affect the adhesive properties, and at the same time deliver the required clinical dose.

[0087J Transdermal patches may be passive or active. Passive transdermal drug delivery systems currently available, such as the nicotine, estrogen and nitroglycerine patches, deliver small-molecule drugs. Many of the newly developed proteins and peptide drugs are too large to be delivered through passive transdermal patches and may be delivered using technology such as electrical assist (iontophoresi ) for large-molecule drugs.

[0088 j iontophoresis is a technique employed for enhancing the flux of ionized substances through membranes by application of electric current One example of an iontophoretic membrane is given, in U.S. Pat. No. 5,080,646 to Theeuwes. The principal mechanisms by which iontophoresi enhances molecular iranspon across the skin are (a) repelling a charged ion from an electrode of the same charge, (b) eleciroosmosis, the convective movement of solvent that occurs through a charged pore in response the preferential passage of counter-ions when an electric Held is applied or (c) increase skin permeability due to application of electrical current.

[0089] in some cases, it may be desirable to administer in the form of a kit, it may comprise a container for containing the separate compositions such as a divided bottle or a divided foil packet. Typically the kit comprises directions for the administration of the separate components. The kit form is particularly advantageous when the separate components axe preferably administered in different dosage forms (e.g.. oral and parenteral), are administered at different dosage intervals, or when titration of the individual components of the combination is desired by the prescribing physician,

{0090] An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a plastic material that may be transparent. During the packaging process recesses are formed in the plastic foil. The recesses have the size and shape of the tablets or capsules to be packed Next, the tablets or capsules are placed in the recesses and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are sealed in the recesses between the plastic foil and the sheet, in some embodiments the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.

|009.tl Methods and compositions for the treatment, of neurodegenerative diseases. Among other things, herein is provided a method of treating neurodegenerative diseases comprising administering to a patient in need thereof a therapeutically effective amount of compound of Formula 1:

Formula Ϊ





a is independently 1, 2, 3, 4 or 5;

a is independently 2,3 or 7;

each b is independently 3, 5 or 6;

e is independently L 2 or 6;

c and d are each independently H, Ό, -OH. ~OD, C-C ₃ -alkyl, -NH> or -CQCH ₃ .

Methods for using compounds of formula 1:

The invention also includes methods for treating neurodegenerative disorders like Alzheimer's disease, Lewy body disease, Huntington's disease. Amyotrophic lateral sclerosis (ALS) and Parkinson's disease. They are also used for the treatment of depression, anxiety and other neurological disorders.

METHODS OF MAKING

10093 J Examples of synthetic pathways useful for making compounds of formula I are set forth in example below and generalized in scheme 1.

Scheme- 1 :

H _a O 0 °C-rt, 3 h

0°C . 3 5 h

11

[0094] Step- ! : Synthesis of compound 2:

H ₂ 0

1

0°C, 3,5 h

rt.2 b

|0095| To an ice cold solution of trifluoroacetic anhydride ( 194.6g, 0.926mol) in toluene (680 ml) was added dropwise a solution of compound 1 ( 1 1 3.22 g. 0.85 mol) i toluene (50 ml) and. stirred under ice cooling for 3.5 h. a solution of KOH (67.25 g, 1.2 mol) in water (1.000 ml) was then, added and the reaction mixture stirred for further 2 h at room temperature. The solid % was collected by .filtration, washed with water (680 mi ), and dried to give 152 g (78%) of a white solid. Mp-153 ' ^' C. The solution was evaporated and the crystals were collected by filtration, washed with water and dried. The second crop (25 g) was crystallized from a mixture of hexane and ethyl acetate to give 18 g of white solid, 2. The total yield was 87%.

{0096J Step-2: Synthesis of compound 4:

|0O97] To a suspension of AICI3 (89.2 g, 0.67 mol) in 1,2-dichloroethane (600 ml) was added chloroacetyl chloride 3 (55,7 ml, 0.7 mol) dropwise at 0 °C under nitrogen for 20 mi and left to warm to room temperature. To this mixture was added compound 2 (34.4 g, 0.15 mol) over a period of 3 h at room temperature. The resulting mixture was then stirred for an additional 30 min and poured into a mixture of ice cold water ( 1 .5 lit) and 1,2-dicbloroethane ( 1 lit), the mixture was stirred for 5 min, and the layers were separated. The aqueous layer was extracted with. 1,2-dichloroethane (2x750 ml). The combined organic layers were washed with (2x900 ml) water and 5% aqueous NaHC(¾ (2x900 ml). The organic layer was dried and the solvent was evaporated to give a solid which was crystallized from ethane to give 31.2 g (68%) of white solid, 4. MEM 66 "C.

{0098] Step-3 : Synthesis of compound 5:

{0099] Compound 4 (30.57 g,0.1 mol) was dissolved in anhydrous dichloromethane (210 ml) and m-CPBA (70%, 44,87 G, 0.25 mol) was added in one portion. The suspension was cooled to 0 ^l 'C, and trifluoroaetic acid (1 1.4 g, 0.1 mol) was added dropwise over 10 rain. The reaction mixture was protected from light, and the mixture was stirred for 5 days at room temperature, poured into 300 ml water, neutralized with ammonium hydroxide solution. The layers were separated, and the aqueous layer was extracted with dichlormethane (200 ml). The combined organic layers were dried and the solvent was evaporated to give a solid which was crustailized from ethanol to give 15 g(48%) of white solid, 5, MP-170 T.

{00100} Step-4: Sy nthesis of compound 6:

{00101} A. suspension of compound 5 (25.4g, 0.1 1 mol) and K2C03 (38 g, 0.275 mol) in a mixture of methanol (275 ml) and water ( 175 ml) was stirred at 70 ⁽ 'C for 1.5 h. Methanol was removed in vacuo and the aqueous phase was neutralized with 10% aqueous HC1. The mixture was filtered and the solid washed with water. The mother liquor was neutralized and filtered. The brown solid was crystallized from methanol to give 7 g (43%) of compound 6, MP-200 °C. [00102} Step-5: Synthesis of compound 8;

[00103} A mixture of amino indanoi 6 (35 mmol), propargyi bromide 7 (35 mmol) and potassium carbonate (35 mmol) in DMA ( 1.00 ml) was stirred at room temperature (RT) for .24 hours. The reaction mixture was filtered, diluted with water (200 ml) and extracted with toluene (4x 100 ml). The organic extracts were combined, dried and evaporated to dryness under reduced pressure. The residue was then subjected to flash column chromatography (hexane:EtOAc, 1: 1 ) to yield compound 8.

{00104] Step-6: Synthesis of compound 10;

[00105] Acid 9 (10 mmol) was taken in a RB added benzene and cooled to 0 °C and added thionyl chloride (1 3 mmol) dropwise and stirred the reaction mixture at same temperature for 4 h. After completion of the reaction as indicated b TLC, benzene was distilled and the crude acid chloride 10 was used for the next step.

[00106} Step-7: S nthesis of compound 1 1

1 1 001071 NaH (15 mrnol) was taken in a B, added DMF,cooled to 0°C and added Compound & in DMF ( 10 mmol) dropwise with stirring. The stirring was continued for 20 min and then added compound 10, stirred the reaction mixture at room temperature for 4h. After completion of the reaction the mixture was cooled to 0°C and added ice cold water dropwise. The reaction mixture was extracted with diethyl ether and the organic layer was dried over Na?S0 and evaporated to get the crude product which was purified through column to yield the final compound 11. MF: C20H25NO2S2 ; Mol. W : 375. Ϊ3 ; Elemental Analysis: C, 63.96; H, 6.71 ; N, 3.73; O, 8,52; S, 17.08

EQUIVALENTS 001081 The present disclosure provides among other things compositions and methods for treating neurodegenerative diseases and their complications. While specific embodiments of the subject disclosure have been discussed, the above specification is illustrative and not restrictive. Many variations of the systems and methods herein will become apparent to those skilled in the art upo review of this specification. The full scope of the claimed systems and methods should be determined by reference to the claims, along with their full scope of equivalents, and the specification, along with such variations.

INCORPORATION BY REFERENCE

|00l09j All publications and patents mentioned herein, including those items listed above, are hereby incorporated by reference in their entirety as if each individual publication or patent was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control .